From microRNA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment (Review)

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 985-994

  Piva, Roberta ^a   Spandidos, Demetrios A ^b   Gambari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

AntagomiR; Breast cancer; MicroRNA replacement therapy; Micrornas; Mir 221; P27KIP1; Peptide nucleic acid; Slug

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; MICRORNA 10B; MICRORNA 145; MICRORNA 155; MICRORNA 221; MICRORNA 222; MICRORNA 27A; MICRORNA 29B; MICRORNA 302; MICRORNA 335; MICRORNA 33A; MICRORNA 34A; MICRORNA 381; MICRORNA 596; MICRORNA 92; PEPTIDE NUCLEIC ACID; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UPREGULATION;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84882344200     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2059     Document Type: Article

References (101)

1. Filipowicz W, Jaskiewicz L, Kolb FA and Pillai RS: Post transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struc Biol 15: 331-341, 2005.
2. He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004.
3. Kozomara A and Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39: D152-D157, 2011.
4. Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597-610, 2010.
5. Sontheimer EJ and Carthew RW: Silence from within: endogenous siRNAs and miRNAs. Cell 122: 9-12, 2005.
6. Taccioli C, Fabbri E, Visone R, Volinia S, Calin GA, Fong LY, et al: UCbase and miRfunc: a database of ultraconserved sequences and microRNA function. Nucleic Acids Res 37: D41-D48, 2009.
7. Griffiths-Jones S: miRBase: the microRNA sequence database. Methods Mol Biol 342: 129-138, 2006.
8. Witwer KW: Data submission and quality in microarray-based microRNA profiling. Clin Chem 59: 392-400, 2013.
9. Sablok G, Milev I, Minkov G, Minkov I, Varotto C, Yahubyan G, and Baev V: isomiRex: Web-based identification of microRNAs, isomiR variations and differential expression using next-generation sequencing datasets. FEBS Lett: Jul 4, 2013 (Epub ahead of print).
10. Russo F, Di Bella S, Nigita G, Macca V, Laganà A, Giugno R, Pulvirenti A and Ferro A: miRandola: extracellular circulating microRNAs database. PLoS One 7: e47786, 2012.
11. Krützfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, Manoharan M and Stoffel M: Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 35: 2885-2892, 2007.
12. Dalmay T: Mechanism of miRNA-mediated repression of mRNA translation. Essays Biochem 54: 29-38, 2013.
13. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G and Liu Y: miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 37: D98-D104, 2009.
14. Subramanian S and Steer CJ: MicroRNAs as gatekeepers of apoptosis. J Cell Physiology 223: 89-98, 2010.
15. Wang YM and Blelloch R: Cell cycle regulation by MicroRNAs in embryonic stem cells. Cancer Res 69: 4093-4096, 2010.
16. Alvarez-Garcia I and Miska EA: MicroRNA functions in animal development and human disease. Development 132: 4653-4662, 2005.
17. Tsai LM and Yu D: MicroRNAs in common diseases and potential therapeutic applications. Clin Exp Pharmacol Physiol 7: 102-107, 2010.
18. Hemida MG, Ye X, Thair S and Yang D: Exploiting the therapeutic potential of microRNAs in viral diseases: expectations and limitations. Mol Diagn Ther 14: 271-282, 2010.
19. Kota SK and Balasubramanian S: Cancer therapy via modulation of micro RNA levels: a promising future. Drug Discov Today 15: 733-740, 2010.
20. Bader AG, Brown D and Winkler M: The promise of microRNA replacement therapy. Cancer Res 70: 7027-7030, 2010.
21. Sibley CR, Seow Y and Wood MJ: Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 18: 466-476, 2010.
22. Ge YF, Sun J, Jin CJ, Cao BQ, Jiang ZF and Shao JF: AntagomiR-27a targets FOXO3a in glioblastoma and suppresses U87 cell growth in vitro and in vivo. Asian Pac J Cancer Prev 14: 963-968, 2013.
23. Rather MI, Nagashri MN, Swamy SS, Gopinath KS and Kumar A: Oncogenic microRNA-down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. J Biol Chem 288: 608-618, 2013.
24. Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W, Zhou Y, Ou Y, Lin X, Lin Y, Xu D, Zhou Y and Yan G: Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer 10: 59, 2011.
25. Haug BH, Henriksen JR, Buechner J, Geerts D, Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B and Einvik C: MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis 32: 1005-1012, 2011.
26. Tang H, Liu X, Wang Z, She X, Zeng X, Deng M, Liao Q, Guo X, Wang R, Li X, Zeng F, Wu M and Li G: Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res 1390: 21-32, 2011.
27. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA: Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28: 341-347, 2010.
28. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG and Ciafrè SA: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 3: e4029, 2008.
29. Scheibner KA, Teaboldt B, Hauer MC, Chen X, Cherukuri S, Guo Y, Kelley SM, Liu Z, Baer MR, Heimfeld S and Civin CI: MiR-27a functions as a tumor suppressor in acute leukemia by regulating 14-3-3. PLoS One 7: e50895, 2012.
30. Endo H, Muramatsu T, Furuta M, Uzawa N, Pimkhaokham A, Amagasa T, Inazawa J and Kozaki K: Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis 34: 560-569, 2013.
31. Liang Z, Ahn J, Guo D, Votaw JR and Shim H: MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res 30: 1008-1016, 2013.
32. Thomas M, Lange-Grünweller K, Weirauch U, Gutsch D, Aigner A, Grünweller A and Hartmann RK: The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 31: 918-928, 2012.
33. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK and Aigner A: MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71: 5214-5224, 2011.
34. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D and Bader AG: Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930, 2010.
35. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG and Slack FJ: Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19: 1116-1122, 2011.
36. Wu Y, Crawford M, Mao Y, Lee RJ, Davis IC, Elton TS, Lee LJ and Nana-Sinkam SP: Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. Mol Ther Nucleic Acids 2: e84, 2013.
37. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ and Marcucci G: Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res 19: 2355-2367, 2013.
38. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH and Agami R: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124: 1169-1181, 2006.
39. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH and Agami R: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol 604: 17-46, 2007.
40. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Puré E and Agami R: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10: 202-210, 2008.
41. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA and Farace MG: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282: 23716-23724, 2007.
42. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046, 2009.
43. Hurst DR, Edmonds MD and Welch DR: Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 69: 7495-7498, 2009.
44. Wotschofsky Z, Liep J, Meyer HA, Jung M, Wagner I, Disch AC, Schaser KD, Melcher I, Kilic E, Busch J, Weikert S, Miller K, Erbersdobler A, Mollenkopf HJ and Jung K: Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci 8: 1363-1374, 2012.
45. Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D and Schiemann WP: TGF-upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 123: 150-163, 2013.
46. Welch DR and Hurst DR: Unraveling the 'TGF-paradox' one metastamir at a time. Breast Cancer Res 15: 305, 2013.
47. Moldovan L, Batte K, Wang Y, Wisler J and Piper M: Analyzing the circulating microRNAs in exosomes/extracellular vesicles from serum or plasma by qRT-PCR. Methods Mol Biol 1024: 129-145, 2013.
48. Chen X, Liang H, Zhang J, Zen K and Zhang CY: Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 3: 28-37, 2012.
49. Kosaka N and Ochiya T: Unraveling the mystery of cancer by secretory microRNA: horizontal microRNA transfer between living cells. Front Genet 2: 97, 2011.
50. Chen X, Liang H, Zhang J, Zen K and Zhang CY: Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 22: 125-132, 2012.
51. Ramachandran S and Palanisamy V: Horizontal transfer of RNAs: exosomes as mediators of intercellular communication. Wiley Interdiscip Rev RNA 3: 286-293, 2012.
52. Muralidharan-Chari V, Clancy JW, Sedgwick A and D'Souza-Schorey C: Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci1 23: 1603-1611, 2010.
53. Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV and Croce CM: Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 6: 458-472, 2012.
54. Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, Tzeng CR, Yang PC and Chen HW: miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res 13: R116, 2011.
55. Iorio MV and Croce CM: Causes and consequences of microRNA dysregulation. Cancer J 18: 215-222, 2012.
56. Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J, Xu X, Zhu Y, Li S, Zheng X and Xie L: MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells 36: 62-68, 2013.
57. He J, Deng Y, Yang G and Xie W: MicroRNA-203 down-regulation is associated with unfavorable prognosis in human glioma. J Surg Oncol 108: 121-125, 2013.
58. Iorio MV and Croce CM: MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27: 5848-5856, 2009.
59. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K and Croce CM: Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA 109: 3024-3029, 2012.
60. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, Jacob ST and Majumder S: Anti-microRNA-222 (anti-miR-222) and-181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 286: 42292-42302, 2011.
61. Shah MY and Calin GA: MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med 3: 56, 2011.
62. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF and Dornan D: miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal 4: pt5, 2011.
63. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D and Richer JK: MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer 1: 306-319, 2010.
64. Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y and Yamashita H: Distinct expressions of microRNAs that directly target estrogen receptor in human breast cancer. Breast Cancer Res Treat 130: 331-339, 2011.
65. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF and Dornan D: TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal 4: ra41, 2011.
66. Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP and White BA: Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 132: 75-85, 2012.
67. Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L and Seth A: miR-221 is down-regulated in TMPRSS2: ERG fusion-positive prostate cancer. Anticancer Res 31: 403-410, 2011.
68. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression analysis in triple negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 10: 507-517, 2011.
69. Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK and Weidhaas JB: Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle 10: 90-99, 2011.
70. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30: 1082-1097, 2011.
71. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI and Tan M: MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285: 21496-21507, 2010.
72. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, Nephew KP and Croce CM: MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 102: 706-721, 2010.
73. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI and Kovalchuk O: Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127: 1785-1794, 2010.
74. Lambertini E, Lolli A, Vezzali F, Penolazzi L, Gambari R and Piva R: Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells. BMC Cancer 12: 445, 2012.
75. Zhao R, Wu J, Jia W, Gong C, Yu F, Ren Z, Chen K, He J and Su F: Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 34: 675-680, 2011.
76. Velu CS and Grimes HL: Utilizing antagomiR (antisense microRNA) to knock down microRNA in murine bone marrow cells. Methods Mol Biol 928: 185-195, 2012.
77. Poltronieri P, D'Urso PI, Mezzolla V and D'Urso OF: Potential of anti-cancer therapy based on anti-miR-155 oligonucleotides in glioma and brain tumours. Chem Biol Drug Des 81: 79-84, 2013.
78. Ma D, Tao X, Gao F, Fan C and Wu D: miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 4: 483-488, 2012.
79. Nielsen PE, Egholm M, Berg RH and Buchardt O: Sequence selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254: 1497-1500, 1991.
80. Demidov VV and Frank-Kamenetskii MD: Sequence-specific targeting of duplex DNA by peptide nucleic acids via triplex strand invasion. Methods 23: 108-122, 2001.
81. Gambari R: Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr Pharm Des 7: 1839-1862, 2001.
82. Karkare S and Bhatnagar D: Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino. Appl Microbiol Biotechnol 71: 575-586, 2006.
83. Nielsen PE: Antisense peptide nucleic acids. Curr Opin Mol Ther 2: 282-287, 2002.
84. Soomets U, Hällbrink M and Langel U: Antisense properties of peptide nucleic acids. Front Biosci 4: D782-D786, 1999.
85. Ray A and Nordén B: Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. FASEB J 14: 1041-1060, 2000.
86. Nielsen PE: Targeting double stranded DNA with peptide nucleic acid (PNA). Curr Med Chem 8: 545-550, 2001.
87. Gambari R: Biological activity and delivery of peptide nucleic acids (PNA)-DNA chimeras for transcription factor decoy (TFD) pharmacotherapy. Curr Med Chem 11: 1253-1263, 2004.
88. Corradini R, Sforza S, Tedeschi, T, Totsingan F and Marchelli R: Peptide nucleic acids with a structurally biased backbone: effects of conformational constraints and stereochemistry. Curr Top Med Chem 7: 681-694, 2007.
89. Sforza S, Tedeschi T, Calabretta A, Corradini R, Camerin C, Tonelli R, Pession A and Marchelli R: A peptide nucleic acid embedding a pseudopeptide nuclear localization sequence in the backbone behaves as a peptide mimic. Eur J Org Chem 13: 2441-2444, 2010.
90. Sforza S, Corradini R, Ghirardi S, Dossena A and Marchelli R: DNA binding of a D-Lysine-based chiral PNA: direction control and mismatch recognition. Eur J Org Chem 16: 2905-2913, 2000.
91. Sforza S, Tedeschi T, Corradini R and Marchelli R: Induction of helical handedness and DNA binding properties of peptide nucleic acids (PNAs) with two stereogenic centres. Eur J Org Chem 35: 5879-5885, 2007.
92. Tedeschi T, Sforza S, Corradini R and Marchelli R: Synthesis of new chiral PNAs bearing a dipeptide-mimic monomer with two lysine-derived stereogenic centres. Tetrahedron Lett 46: 8395-8399, 2005.
93. Dragulescu-Andrasi A, Zhou P, He G and Ly DH: Cell-permeable GPNA with appropriate backbone stereochemistry and spacing binds sequence-specifically to RNA. Chem Commun 3: 244-246, 2005.
94. Brognara E, Fabbri E, Aimi F, Manicardi A, Bianchi N, Finotti A, Breveglieri G, Borgatti M, Corradini R, Marchelli R and Gambari R: Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int J Oncol 41: 2119-2127, 2012.
95. Gambari R, Fabbri E, Borgatti M, Lampronti I, Finotti A, Brognara E, Bianchi N, Manicardi A, Marchelli R and Corradini R: Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development. Biochem Pharmacol 82: 1416-1429, 2011.
96. Fabani MM and Gait MJ: miR-122 targeting with LNA/2'-O- methyloligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 14: 336-346, 2008.
97. Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, Torres AG, Smith KGC, et al: Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res 38: 4466-4475, 2010.
98. Fabbri E, Manicardi A, Tedeschi T, Sforza S, Bianchi N, Brognara E, Finotti A, Breveglieri G, Borgatti M, Corradini R, Marchelli R and Gambari R: Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). Chem Med Chem 6: 2192-2202, 2011.
99. Fabbri E, Brognara E, Borgatti M, Lampronti I, Finotti A, Bianchi N, Sforza S, Tedeschi T, Manicardi A, Marchelli R, Corradini R and Gambari R: miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs. Epigenomics 3: 733-745, 2011.
100. Manicardi A, Fabbri E, Tedeschi T, Sforza S, Bianchi N, Brognara E, Gambari R, Marchelli R and Corradini R: Cellular uptakes, biostabilities and anti-miR-210 activities of chiral arginine-PNAs in leukaemic K562 cells. Chembiochem 13: 1327-1337.
101. Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, Zeng YX and Shao JY: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 13: R2, 2011.